Pharmaceutical News

RSS

Ramizol drug shows promise in treatment of Clostridium difficile infections

A scientific paper released today in the Journal of Antibiotics presents the pre-clinical development of Ramizol, a first generation drug belonging to a new class of styrylbenzene antibiotics with a novel mechanism of action.

19 May 2016

Flavopiridol drug could be effective strategy to impair brain cancer growth

Glioblastoma, the most common form of brain cancer is a deadly disease for which at present there is no cure. Now, researchers have published research results that show how repurposing the old drug flavopiridol could be an effective strategy to cut short sugar availability and impair cancer growth.

19 May 2016

Hydroxyurea treatment improves pulmonary function decline in children with sickle cell disease

For the first time, researchers were able to demonstrate that children diagnosed with sickle cell disease showed improvement in lung function after treatment with hydroxyurea, a treatment that is underused despite its demonstrated benefits.

19 May 2016

ICS users may be at greater risk for nontuberculous mycobacteria pulmonary disease

Patients with obstructive lung disease who take inhaled corticosteroids (ICS) may be at greater risk for nontuberculous mycobacteria pulmonary disease (NTM PD), according to new research presented at the ATS 2016 International Conference.

19 May 2016

Mouse model of depression can help better understand how ketamine functions

New research demonstrates the effectiveness of ketamine to treat depression in a mouse model of the disease and brings together two hypotheses for the cause of depression.

19 May 2016

Tecentriq drug gets FDA approval to treat urothelial carcinoma

The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product in its class (PD-1/PD-L1 inhibitors) approved to treat this type of cancer.

19 May 2016

Taking pregabalin drug during pregnancy could lead to major birth defects

A drug commonly used to treat pain, epilepsy, anxiety and other brain health disorders may be associated with an increased risk of major birth defects, according to a study published in the May 18, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology.

19 May 2016

Effective chemotherapeutic drug may induce permanent hearing loss in Cockayne syndrome individuals

The chemotherapy drug cisplatin can kill cancer, but it can also cause permanent hearing loss.

19 May 2016

Easy, immediate access to effective antidotes could help reduce deaths from opioid overdose

Over the past 15 years, deaths caused by heroin and prescription opioid overdoses have quadrupled despite the existence of a highly effective antidote. The cover story in Chemical & Engineering News, the weekly news magazine of the American Chemical Society, explores what it might take to turn the tide.

19 May 2016

Neurotoxic effects of chemotherapy may impair cognitive function in young ALL patients

The neurotoxic effects of chemotherapeutic drugs on the developing brains of young patients with acute lymphoblastic leukemia (ALL) may impair their cognitive functioning by disrupting the formation of neural networks that connect brain regions and transfer information.

19 May 2016

Melatonin can be of great value for elderly people suffering from hypertension

The older we get, the more likely our circadian rhythms are disrupted. For example, blood pressure (BP), not only tends to increase but as well become more irregular. Luckily, as we show in our research, melatonin helps to ameliorate both trends.

18 May 2016

Take complementary medicines with care

Following the broadcast of the ABC’s Four Corners episode last night on complementary medicines, NPS MedicineWise is reminding people to take these medicines with care.

18 May 2016

Prenatal exposure to SSRIs linked to lower birth weight, gestational length

A new study, published today in the International Journal of Epidemiology, has found that prenatal exposure to selective serotonin reuptake inhibitors (SSRIs) has a significant association with lower birth weight and gestational length.

17 May 2016

Novel therapeutic approach to treat leukaemia patients

Cancer cells have an abnormal cell division and survival machinery - they grow faster than they die. For their permanent development, they produce an excess of growth factors and nutrients and block the body's own safety mechanisms.

17 May 2016

Experimental hepatitis C drug slows down development of Zika in mice

Virologists from KU Leuven, Belgium, have shown that an experimental antiviral drug against hepatitis C slows down the development of Zika in mice. The research team was led by Professor Johan Neyts from the Laboratory of Virology and Chemotherapy.

17 May 2016

Antipsychotic drug users may twice as likely to experience heart attack than non-users

A review of nine observational studies found evidence supporting an increased risk of heart attacks in patients taking antipsychotic drugs.

17 May 2016

FDA approves additional indication for Eisai's anticancer agent Lenvima in combo with Everolimus for advanced renal cell carcinoma

Eisai Co., Ltd. has announced that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional indication for Eisai's in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.

16 May 2016

Pluristem completes enrollment in Phase II intermittent claudication trial

Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced it has completed the planned enrollment of 150 patients in a global Phase II trial of its PLacental eXpanded (PLX)-PAD cells for the treatment of intermittent claudication (IC), a peripheral artery disease (PAD). The double blind, randomized, placebo controlled trial enrolled 50 patients since October 2015 in the U.S., Germany, Israel, and South Korea.

16 May 2016

Neos announces U.S. launch of Adzenys XR-ODT for ADHD

Neos Therapeutics, Inc., a pharmaceutical company with a late‐stage pipeline of innovative extended-release (XR) product candidates for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that Adzenys XR-ODT™ is in distribution channels and is now available to prescribe for patients with ADHD in the United States.

16 May 2016

Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

New analyses presented at the American Thoracic Society’s 2016 annual conference (ATS 2016) further add to the efficacy and safety profile of OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF).

16 May 2016

Pharmaceutical News

Ramizol drug shows promise in treatment of Clostridium difficile infections

Flavopiridol drug could be effective strategy to impair brain cancer growth

Hydroxyurea treatment improves pulmonary function decline in children with sickle cell disease

ICS users may be at greater risk for nontuberculous mycobacteria pulmonary disease

Mouse model of depression can help better understand how ketamine functions

Tecentriq drug gets FDA approval to treat urothelial carcinoma

Taking pregabalin drug during pregnancy could lead to major birth defects

Effective chemotherapeutic drug may induce permanent hearing loss in Cockayne syndrome individuals

Easy, immediate access to effective antidotes could help reduce deaths from opioid overdose

Neurotoxic effects of chemotherapy may impair cognitive function in young ALL patients

Melatonin can be of great value for elderly people suffering from hypertension

Take complementary medicines with care

Prenatal exposure to SSRIs linked to lower birth weight, gestational length

Novel therapeutic approach to treat leukaemia patients

Experimental hepatitis C drug slows down development of Zika in mice

Antipsychotic drug users may twice as likely to experience heart attack than non-users

FDA approves additional indication for Eisai's anticancer agent Lenvima in combo with Everolimus for advanced renal cell carcinoma

Pluristem completes enrollment in Phase II intermittent claudication trial

Neos announces U.S. launch of Adzenys XR-ODT for ADHD

Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News